Advanced Search
ZHANG Yu, YAN Fang, XIAO Yibei. Development of VISTA in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403
Citation: ZHANG Yu, YAN Fang, XIAO Yibei. Development of VISTA in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403

Development of VISTA in tumor immunotherapy

  • V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a member of the B7 family that maintains homeostasis in T cells and myeloid cells.Blocking VISTA inhibits tumor development in in vitro and in vivo trials, and is an important target for tumor immunotherapy.This review focuses on its structural features, expression and biological functions in tumor microenvironment, summarizes the current stage of small molecule inhibitors and antibodies targeting VISTA, and discusses the research approaches.It aims to provide a rationale for subsequent study on VISTA and the development of related immune checkpoint antitumor drugs.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return